ReviewThe British journal of radiology2023
The lung cancers: staging and response, CT,
Review in The British journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Artificial intelligence for lung cancer: a systematic review of head‑to‑head CT, FDG PET/CT, and multimodal models across screening, staging, and prognosis.BMC medical imaging · 2026Pooled it
- PET radiomics for histologic subtype classification of non-small cell lung cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- [Frontiers in medicine · 2024Pooled it
- [Frontiers in medicine · 2024Pooled it
- Radiomics in distinguishing between lung adenocarcinoma and lung squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Deep integration of clinical metadata with [European journal of nuclear medicine and molecular imaging · 2026Article
- Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden.Research square · 2026Article
- Development of an adjustable dynamic phantom for testing deviceless motion correction algorithm in PET.Medical physics · 2026Article
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Article
- CT-to-PET Synthesis in the Head-Neck and Thoracic Region via Conditional 3D Latent Diffusion Modeling.Bioengineering (Basel, Switzerland) · 2026Article
- Imaging of Small Cell Lung Cancer: An Updated Overview of Current and Emerging Applications.Radiology. Imaging cancer · 2026Review
- Non-Small-Cell Lung Cancer: From Histopathological Classification to Precision Oncology-A Narrative Review.Journal of clinical medicine · 2026Review
- Application of artificial intelligence in lung cancer diagnosis, therapy, and prognosis.BMC medical genomics · 2026Review
- The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics.Frontiers in oncology · 2026Review
- Clinical study ofPeerJ · 2026Article
- O-GlcNAcylation levels predict radiotherapy outcome in non-small cell lung cancer.Translational lung cancer research · 2025Article
- Histopathological and Molecular Predictors of the First Site of Dissemination in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Integrin αvβ6-Targeted PET/CT Imaging of Non-Small Cell Lung Cancer with [Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Observational
- The Role of 18F-FDG PET/CT in Monitoring Immunotherapy Response in Non-Small Cell Lung Cancer: Current Evidence and Challenges: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in both sexes combined. Recent years have seen major advances in the diagnostic and treatment options for patients with non-small-cell lung cancer (NSCLC), including the routine use of 2-deoxy-2[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.